Table 2.
Resistance Mechanisms | MDR-UPEC clinical strains | Total % (n = 82) | XDR-UPEC clinical strains | Total % (n = 21) | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Percentage in the phylogenetic groups | Percentage in the phylogenetic groups | |||||||||
A% (n = 5) | B1% (n = 0) | B2% (n = 32) | D% (n = 45) | A% (n = 2) | B1% (n = 0) | B2% (n = 10) | D% (n = 9) | |||
intl1 | 40 (2) | 0 (0) | 43.75 (14) | 44.43 (20) | 43.90 (36) | 100 (2) | 0 (0) | 30 (3) | 55.56 (5) | 47.61 (10) |
intl2 | 0 (0) | 0 (0) | 3.12 (1) | 2.22 (1) | 2.43 (2) | 50 (1) | 0 (0) | 10 (1) | 0 (0) | 9.52 (2) |
intl3 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
ESBLs | 20 (1) | 0 (0) | 28.12 (9) | 11.12 (5) | 18.29 (15) | 100 (2) | 0 (0) | 80 (8) | 66.67 (6) | 76.19 (16) |
Class 1 integrase (intl1), class 2 integrase (intl2), class 3 integrase (intl3), and extended-spectrum beta-lactamases (ESBLs).